Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours
Open Access
- 9 May 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 30 (41), 4243-4260
- https://doi.org/10.1038/onc.2011.133
Abstract
Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation and gene expression microarray analysis. CYLD mutant tumours were characterised by an absence of copy-number aberrations apart from LOH chromosome 16q, the genomic location of the CYLD gene. Gene expression profiling of CYLD mutant tumours showed dysregulated tropomyosin kinase (TRK) signalling, with overexpression of TRKB and TRKC in tumours when compared with perilesional skin. Immunohistochemical analysis of a tumour microarray showed strong membranous TRKB and TRKC staining in cylindromas, as well as elevated levels of ERK phosphorylation and BCL2 expression. Membranous TRKC overexpression was also observed in 70% of sporadic BCCs. RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours. These results suggest that TRK inhibition could be used as a strategy to treat tumours with loss of functional CYLD.Keywords
This publication has 79 references indexed in Scilit:
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of actionBiochemical Pharmacology, 2010
- Tumor Mapping in 2 Large Multigenerational Families With CYLD MutationsArchives of Dermatology, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- p62 serves as a shuttling factor for TrkA interaction with the proteasomeBiochemical and Biophysical Research Communications, 2008
- Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signalingNature Genetics, 2008
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Up-regulation of BDNF in Astrocytes by TNF-α: A Case for the Neuroprotective Role of CytokineJournal of Neuroimmune Pharmacology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005